Yosuke Togashi

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Masato Terashima, Kazuko Sakai, Kazuto Nishio, 2017, BMC Cancer.

Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21.

Michiaki Mishima, M. Mishima, Yosuke Togashi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

Kenichi Suda, Masaki Shimoji, Toyoaki Hida, 2015, Clinical Cancer Research.

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing

Masato Terashima, Shuta Tomida, Kazuko Sakai, 2015, PloS one.

Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer.

Masato Terashima, Masatoshi Kudo, Masayuki Kitano, 2015, Cancer letters.